Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study
Bassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients
Ghida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
Tim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Neurodegenerative Disease Management
|
June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
Tim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry
Sifat Sharmin, Charles B Malpas, Izanne Roos, et al.
The Lancet. Neurology
|
September 20, 2024
Differential diagnosis of suspected multiple sclerosis: global health considerations
Jorge Correale, Andrew J Solomon, Jeffrey A Cohen, et al.
CNS Drugs
|
February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
Jodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumab
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 1, 2025
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study
Bassem Yamout, Raed Alroughani, Samar Frouk Ahmed Mohamed, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics
|
March 13, 2026
The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients
Ghida Ismail, Maya Zeineddine, Raed Al-Roughani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 26, 2022
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
Tim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Neurodegenerative Disease Management
|
June 8, 2023
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry
Tim Spelman, Serkan Ozakbas, Raed Alroughani, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 30, 2022
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry
Sifat Sharmin, Charles B Malpas, Izanne Roos, et al.
The Lancet. Neurology
|
September 20, 2024
Differential diagnosis of suspected multiple sclerosis: global health considerations
Jorge Correale, Andrew J Solomon, Jeffrey A Cohen, et al.
CNS Drugs
|
February 14, 2025
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
September 4, 2024
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study
Pakeeran Siriratnam, Paul Sanfilippo, Anneke van der Walt, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years
Jodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumab
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Page
of 9